J Ingelfinger
Overview
Explore the profile of J Ingelfinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwiterovich P, Ingelfinger J, Leibel R, Lauer R, Olson C
Bull N Y Acad Med
. 2009 Mar;
65(10):1154-60.
PMID: 19313079
No abstract available.
2.
Dluhy R, Anderson B, Harlin B, Ingelfinger J, Lifton R
J Pediatr
. 2001 May;
138(5):715-20.
PMID: 11343049
Objectives: To review the childhood course of glucocorticoid-remediable aldosteronism (GRA) in order to provide management guidelines for hypertension in children. Methods: Records for 20 children with GRA (aged 1 month...
3.
Hogg R, Portman R, Milliner D, Lemley K, Eddy A, Ingelfinger J
Pediatrics
. 2000 Jun;
105(6):1242-9.
PMID: 10835064
Objective: The development of this review article evolved from a National Kidney Foundation consensus conference on recent advances in the importance of evaluating and treating proteinuria. From this conference, a...
4.
Agodoa L, Eknoyan G, Ingelfinger J, KEANE W, Mauer M, Mitch W, et al.
Kidney Int Suppl
. 1998 Jan;
63:S144-50.
PMID: 9407444
The incidence and prevalence rates of end-stage renal disease (ESRD) in the United States continue to increase. In 1995, the incidence rate was 262 per million population, with a point...
5.
Gahl W, Ingelfinger J, Mohan P, Bernardini I, Hyman P, Tangerman A
Pediatr Res
. 1995 Oct;
38(4):579-84.
PMID: 8559613
A 4-y-old boy with nephropathic cystinosis and gastrointestinal dysmotility of unknown etiology was treated with i.v. cysteamine over a period of 10 mo. Thirty minutes after a dose of 10...
6.
Tang S, Jung F, Diamant D, Ingelfinger J
Exp Nephrol
. 1994 Mar;
2(2):127.
PMID: 8082004
No abstract available.
7.
Sigmund C, Jones C, Jacob H, Ingelfinger J, Kim U, Gamble D, et al.
Am J Physiol
. 1991 Feb;
260(2 Pt 2):F249-57.
PMID: 1996675
The pathophysiological consequence of targeted production of SV-40 T-antigen to renin-expressing cells in the kidney of transgenic mice is reported. A histopathologic analysis of the kidney from adult transgenic mice...
8.
Sigmund C, Okuyama K, Ingelfinger J, Jones C, Mullins J, Kane C, et al.
J Biol Chem
. 1990 Nov;
265(32):19916-22.
PMID: 2174057
We constructed transgenic mice containing a renin-promoter SV40 T antigen fusion transgene with the intention of inducing neoplasia in renin-expressing cells and isolating renin-expressing cell lines in vitro. We examined...
9.
MISHLER E, Clark J, Ingelfinger J, SIMON M
J Gen Intern Med
. 1989 Jul;
4(4):325-35.
PMID: 2668459
No abstract available.
10.
Dzau V, Ellison K, Brody T, Ingelfinger J, PRATT R
Endocrinology
. 1987 Jun;
120(6):2334-8.
PMID: 3552634
Previous studies have reported the presence of renin mRNAs in several mouse tissues and angiotensinogen mRNAs in various rat tissues. Clarification as to whether renin and angiotensinogen mRNAs are coexpressed...